What is Leerink Partnrs’ Forecast for EHC FY2025 Earnings?

Encompass Health Co. (NYSE:EHC) – Research analysts at Leerink Partnrs raised their FY2025 earnings estimates for shares of Encompass Health in a research note issued to investors on Wednesday, April 30th. Leerink Partnrs analyst W. Mayo now forecasts that the company will earn $4.95 per share for the year, up from their previous estimate of $4.90. The consensus estimate for Encompass Health’s current full-year earnings is $4.80 per share. Leerink Partnrs also issued estimates for Encompass Health’s Q2 2026 earnings at $1.39 EPS, Q3 2026 earnings at $1.24 EPS and Q4 2026 earnings at $1.31 EPS.

Several other research firms have also commented on EHC. UBS Group upped their price objective on Encompass Health from $117.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, April 28th. KeyCorp raised their price target on shares of Encompass Health from $120.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. William Blair reiterated an “outperform” rating on shares of Encompass Health in a research report on Friday, February 7th. Truist Financial restated a “buy” rating and set a $135.00 target price (up from $116.00) on shares of Encompass Health in a research report on Monday, April 28th. Finally, Royal Bank of Canada increased their price target on Encompass Health from $110.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, April 28th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $120.86.

Encompass Health Stock Up 0.7 %

Shares of EHC opened at $116.73 on Friday. The company has a market capitalization of $11.76 billion, a price-to-earnings ratio of 26.17, a PEG ratio of 2.31 and a beta of 0.87. Encompass Health has a 52 week low of $82.74 and a 52 week high of $117.52. The stock’s 50-day moving average price is $101.73 and its 200-day moving average price is $99.23. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84.

Encompass Health (NYSE:EHC) last released its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.18. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the prior year, the business earned $1.12 earnings per share. The business’s quarterly revenue was up 10.6% compared to the same quarter last year.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be given a $0.17 dividend. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.58%. Encompass Health’s dividend payout ratio (DPR) is presently 14.05%.

Insider Transactions at Encompass Health

In related news, CAO Andrew L. Price sold 5,042 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $98.29, for a total transaction of $495,578.18. Following the transaction, the chief accounting officer now directly owns 69,164 shares in the company, valued at approximately $6,798,129.56. The trade was a 6.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP John Patrick Darby sold 10,000 shares of the stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the completion of the sale, the executive vice president now owns 79,710 shares of the company’s stock, valued at approximately $9,149,910.90. The trade was a 11.15 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Encompass Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EHC. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock worth $27,000 after acquiring an additional 137 shares during the period. Colonial Trust Co SC purchased a new position in Encompass Health during the fourth quarter worth about $29,000. Transce3nd LLC acquired a new position in Encompass Health in the 4th quarter valued at about $40,000. CBIZ Investment Advisory Services LLC grew its stake in shares of Encompass Health by 38.7% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock valued at $42,000 after buying an additional 127 shares during the period. Finally, Tompkins Financial Corp acquired a new stake in shares of Encompass Health during the 4th quarter worth approximately $46,000. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.